Smartlab Europe

Dr. Reddy’s introduces Desloratadine ODT in US

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Egypt-Takeda Pharmaceutical Cooperation Boosts R&D Push

Egypt is stepping up its push to reinforce its...

Online Medicine in India Where Ganaton Total Fits in Modern Digestive Care

The demand for online medicine delivery in India has...

Roche AI Factory Expansion to Boost Pharma R&D Capacity

Swiss drugmaker Roche has expanded its artificial intelligence infrastructure...
- Advertisement -

Dr. Reddy’s Laboratories has received the FDA approval and introduced Desloratadine orally disintegrating tablets (ODT) in 2.5mg and 5mg strengths in the US.

Desloratadine ODT is a generic equivalent to Clarinex Reditabs (desloratadine), which according to IMS Health data had total sales of $5.3m in the US for the twelve months ending November 2012.

The company makes Desloratadine ODT of 2.5mg and 5mg strengths available in unit dose packages of 30.

Clarinex Reditabs is indicated to fight allergy with the same strength of Clarinex but with the additional convenience of a rapid disintegration without water.

The prescription nonsedating, antihistamine was approved for the treatment of indoor and outdoor allergies and hives of unknown cause.

Latest stories

Related stories

Egypt-Takeda Pharmaceutical Cooperation Boosts R&D Push

Egypt is stepping up its push to reinforce its...

Online Medicine in India Where Ganaton Total Fits in Modern Digestive Care

The demand for online medicine delivery in India has...

Roche AI Factory Expansion to Boost Pharma R&D Capacity

Swiss drugmaker Roche has expanded its artificial intelligence infrastructure...

Enhertu Priority Review in HER2-Positive Early Breast Cancer

The supplemental Biologics License Application - sBLA for Enhertu...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »